|AT THE COMPANY||AT THE FINANCIAL RELATIONS BOARD|
|Robert V. Toni, President & CEO
J. Blount Swain, CFO
CLOSURE Medical Corporation (919) 876-7800
|For General Info: Paul G. Henning (212) 661-8030
For Analyst Info: Brian Gill (212) 661-8030
For Media Info: Deanne Eagle (212) 661-8030
FOR IMMEDIATE RELEASE: March 31, 1998
DEBRA L. PAWL JOINS CLOSURE MEDICAL CORPORATIONAS VICE PRESIDENT AND GENERAL COUNSEL
Raleigh, NC, March 31, 1998-- CLOSURE Medical Corporation (Nasdaq: CLSR) today announced that Debra L. Pawl, 45, has been named Vice President and General Counsel of the Company.
Ms. Pawl previously served as Patent Manager for J.M. Huber Corporation, a privately held $1.5 billion, multi-industrial natural resources and industrial products company. At Huber, she was responsible for directing all worldwide intellectual property matters, including the drafting and negotiation of a variety of agreements supporting technology transfers, licensing and business partnering arrangements and divestitures.
Prior to joining Huber, Ms. Pawl worked as a patent attorney for several large chemical companies, including Standard Oil, Owens-Corning (NYSE: OWC) and BF Goodrich (NYSE: GR), handling patent applications, patent prosecutions, trademark and general intellectual property matters. Ms. Pawl has a BS and MS in Chemistry/Biology from John Carroll University and a JD degree from the University of Toledo College of Law.
"We are extremely pleased that Debbie has joined CLOSURE Medical Corporation," said Mr. Robert V. Toni, President and Chief Executive Officer. "She will be a valuable asset to the Company on our journey to the leadership position in medical tissue cohesives."
CLOSURE Medical develops, commercializes and manufactures medical cohesive products based on its proprietary cyanoacrylate technology. CLOSURE’s nonabsorbable products may be used to replace sutures and staples for certain topical wound closure applications, while its absorbable products can potentially be used as surgical sealants and cohesives for internal wound closure and management. Currently marketed products include DERMABOND* non-absorbable cohesive used for certain topical wound closure applications, marketed and distributed exclusively by Ethicon, Inc., a subsidiary of Johnson & Johnson, and OctyldentÒ non-absorbable tissue cohesive used in conjunction with antibiotics to treat adult periodontal disease, and the NexabandÒ line of topical cohesives used in veterinary wound closure and management.
*DERMABOND is a trademark of Ethicon, Inc.
To receive CLOSURE’s latest news release and other corporate documents via FAX-- at no cost -- dial 1-800-PRO-INFO. Use Company’s ticker-CLSR.
This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties or other factors not under the Company’s control which may cause actual results, performance or achievements of the Company to be materially different from the results, performance, or other expectations implied by these forward-looking statements. These factors include, but are not limited to, the early stage of commercialization of the Company’s products; scale-up of manufacturing processes; the need for regulatory approval and effects of governmental regulation; technological uncertainties; dependence on marketing partners; and dependence on patents and trade secrets, as well as those detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 1997 and filed with the Securities and Exchange Commission.